CMS (00867) announced that its subsidiary DeMai Pharmaceuticals Limited (DeMai Pharmaceuticals, an innovative pharmaceutical company focused on dermatological health that is applying for independent listing on the Main Board of The Stock Exchange of Hong Kong Limited) together with its subsidiaries received a Drug Clinical Trial Approval Notice issued by China's National Medical Products Administration (NMPA) on August 27, 2025, with the notice received on August 28, 2025.

The NMPA has approved the conduct of clinical trials for povorcitinib (proposed Chinese generic name: Povorcitinib Phosphate Tablets) for the treatment of non-segmental vitiligo and moderate-to-severe hidradenitis suppurativa (HS).

Povorcitinib is a selective oral small molecule JAK1 inhibitor with substance and use patents in specific countries/regions. Currently, povorcitinib is undergoing Phase 3 clinical trials in several overseas countries for non-segmental vitiligo, HS, and nodular prurigo. Additionally, Phase 2 clinical trials for the treatment of asthma and chronic spontaneous urticaria are also in progress.